Media & Resources

TB kills 1.3 million people a year and sickens more than 10 million people annually. A new TB vaccine is needed to reach the global End TB goals. MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB…

NEW YORK and TOKYO — October 13, 2023 — IAVI, a nonprofit scientific research organization, and Japan’s National Institute of Infectious Diseases (NIID), the primary infectious disease research institute funded by the Government of Japan, have signed a memorandum of understanding to strengthen their international cooperation for research and development (R&D) to control infectious diseases. Two…

NEW YORK — JULY 6, 2023 — IAVI is pleased to announce a new award has been granted by the German government to help support the late-stage development of a promising tuberculosis (TB) vaccine candidate, MTBVAC. The German Federal Ministry of Education and Research (BMBF) through the KfW Development Bank has committed to contribute €9.2…

First participants for the Multisite Adolescent Girls and Young Women study screened at the Centre for Family Health Research in Zambia. IAVI has announced the enrolment of the first 29 participants for the Multisite Adolescent Girls and Young Women (MAGY) study at the Centre for Family Health Research in Zambia (CFHRZ). Over the next three…

NEW YORK – JUNE 27, 2023 – IAVI announced today that the first participants have been vaccinated with a Sudan virus (SUDV) vaccine candidate in a first-in-human Phase 1 clinical trial in the U.S. The IAVI-sponsored trial is funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness…

TB kills 1.6 million people a year, causing more deaths than any other single infectious disease apart from COVID-19, and sickens more than 10 million people annually. A new TB vaccine is needed to reach global END TB goals. MTBVAC is a highly promising vaccine candidate that has the potential to be used as an…

Denmark, represented by the Danish Ministry of Foreign Affairs is committed to contribute a total of DKK 20 million (US$3 million) from 2022-2025.

Funding will allow for additional development and testing of IAVI’s single-dose vaccine candidates against the filoviruses Marburg virus and Sudan ebolavirus.